Cariprazine hydrochloride

Cariprazine Hydrochloride is an antipsychotic medication primarily used for the treatment of schizophrenia and bipolar disorder. It is sold under the brand name Vraylar in the United States and Reagila in Europe.

Pharmacology

Cariprazine hydrochloride acts as a partial agonist at the dopamine D2 and D3 receptors, and the serotonin 5-HT1A receptors. It also acts as an antagonist at the 5-HT2A, 5-HT2B, and 5-HT7 receptors. The unique action at the D3 receptor is thought to contribute to its efficacy in the treatment of cognitive symptoms of schizophrenia.

Clinical Use

Cariprazine hydrochloride is approved by the FDA for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder. It is also being investigated for use in the treatment of major depressive disorder and as an adjunct in treatment-resistant depression.

Side Effects

Common side effects of cariprazine hydrochloride include akathisia, insomnia, and weight gain. Less common but more serious side effects can include tardive dyskinesia, neuroleptic malignant syndrome, and increased risk of suicide in young adults.

History

Cariprazine hydrochloride was developed by Gedeon Richter and is marketed in the United States by Allergan. It was approved by the FDA in 2015.

See Also

• Antipsychotic
• Schizophrenia
• Bipolar disorder
• Dopamine
• Serotonin